Trial Profile
A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine For Pre-Exposure Prophylaxis in HIV-Uninfected Men and Transgender Women Who Have Sex With Men
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 16 Jan 2024
Price :
$35
*
At a glance
- Drugs Cabotegravir (Primary) ; Cabotegravir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate
- Indications HIV infections
- Focus Adverse reactions; Registrational; Therapeutic Use
- 10 Jan 2024 According to a ViiV Healthcare media release, the company announced that the Health Canada grants Priority Review status to filed a New Drug Submission (NDS).
- 22 Feb 2023 Results from bone safety sub-study comparing BMD changes over 105 weeks, presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023
- 22 Feb 2023 Results of pre-specified subanalysis (n=1698) assessing the HIV incidence and prevention efficacy of long-acting injectable cabotegravir among US black MSM and TGW who were enrolled in HPTN083, presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023.